Investors & Media

Overview

Webcast ImageWebcast
J.P. Morgan Healthcare Conference (Replay)
01/12/16 at 4:00 p.m. PT
J.P. Morgan Healthcare Conference
Tuesday, January 12, 2016 4:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. The company’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe and effective treatment options. Headquartered in Cambridge, Massachusetts, bluebird bio has operations in the U.S. and Europe.

stock quote

NASDAQ: BlUE (common stock)

Refresh Quote
ExchangePriceChange (%)Volume
NASDAQ GS (US Dollar)
$43.32
 Stock is Down 2.67 (5.81%)
1,375,613
Data provided by Nasdaq. Minimum 15 minutes delayed.

Investor Contact

Manisha Pai

Sr. Director, Investor Relations

(617) 245-2107

investor@bluebirdbio.com


Media Contact

Dan Budwick

Senior Vice President, Media Relations

Pure Communications Inc.

(973) 271-6085

dan@purecommunicationsinc.com